AR091699A1 - Derivado de indol carboxamida - Google Patents
Derivado de indol carboxamidaInfo
- Publication number
- AR091699A1 AR091699A1 ARP130102421A AR091699A1 AR 091699 A1 AR091699 A1 AR 091699A1 AR P130102421 A ARP130102421 A AR P130102421A AR 091699 A1 AR091699 A1 AR 091699A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- group
- halogen
- substituted
- substituents selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales, donde Y es N o CR¹; R¹, R³ y R⁴ son iguales o diferentes el uno del otro y son cada uno alquilo inferior que puede estar sustituido con uno o más sustituyentes seleccionados del grupo integrado por halógeno, -OH, -O-alquilo inferior, -O-halógeno-alquilo inferior y -NR⁹R¹⁰, H o halógeno; R² es alquilo inferior que puede estar sustituido con uno o más sustituyentes seleccionados del grupo integrado por halógeno y ciano, y R² puede estar combinado con R¹ para formar -(CH₂)ₙ-, o R² puede estar combinado con R³ para formar -(CH₂)ₙ-; n es 2 ó 3; R⁵¹ y R⁵² son iguales o diferentes el uno del otro y son alquilo inferior que puede estar sustituido con uno o más sustituyentes seleccionados del Grupo G², cicloalquilo que puede estar sustituido con uno o más sustituyentes seleccionados del Grupo G¹, o H, y además, R⁵¹ y R⁵² pueden estar combinados con un átomo de nitrógeno al que están unidos para formar amino cíclico que puede estar sustituido con uno o más sustituyentes seleccionados del Grupo G¹; X es un enlace, -NR¹¹- o -NR¹¹-O-; R¹¹ es H o alquilo inferior; R⁶ es alquilo inferior que puede estar sustituido con uno o más sustituyentes seleccionados del Grupo G⁴, o cicloalquilo que puede estar sustituido con uno o más sustituyentes seleccionados del Grupo G³, además, cuando -X-R⁶- es NR¹¹-R⁶, R⁶ y R¹¹ pueden estar combinados con un átomo de nitrógeno al que están unidos para formar amino cíclico que puede estar sustituido con uno o más sustituyentes seleccionados del Grupo G³; R⁷ y R⁸ son iguales o diferentes el uno del otro y son cada uno alquilo inferior que puede estar sustituido con uno o más sustituyentes seleccionados del grupo integrado por halógeno, -OH, y -O-halógeno-alquilo inferior o H; Grupo G¹ y Grupo G³ incluyen alquilo inferior, halógeno-alquilo inferior, halógeno, -OH, -O-alquilo inferior, -O-halógeno-alquilo inferior y -NR⁹R¹⁰; Grupo G² y Grupo G⁴ incluyen halógeno, -OH, -O-alquilo inferior, -O-halógeno-alquilo inferior, cicloalquilo que puede estar sustituido con uno o más átomos de halógeno, -O-(cicloalquilo que puede estar sustituido con uno o más átomos de halógeno) y -NR⁹R¹⁰; y R⁹ y R¹⁰ son iguales o diferentes el uno del otro y son H o alquilo inferior.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012154322 | 2012-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091699A1 true AR091699A1 (es) | 2015-02-25 |
Family
ID=49916054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102421 AR091699A1 (es) | 2012-07-10 | 2013-07-08 | Derivado de indol carboxamida |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9376449B2 (es) |
| EP (1) | EP2873660B1 (es) |
| JP (1) | JP6131951B2 (es) |
| KR (1) | KR102119372B1 (es) |
| CN (1) | CN104428286B (es) |
| AR (1) | AR091699A1 (es) |
| AU (1) | AU2013287758A1 (es) |
| BR (1) | BR112015000709B1 (es) |
| CA (1) | CA2878663C (es) |
| EA (1) | EA026090B1 (es) |
| ES (1) | ES2630653T3 (es) |
| IL (1) | IL236406A0 (es) |
| MX (1) | MX361463B (es) |
| PH (1) | PH12015500003A1 (es) |
| PL (1) | PL2873660T3 (es) |
| PT (1) | PT2873660T (es) |
| TW (1) | TW201416351A (es) |
| WO (1) | WO2014010602A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150368220A1 (en) * | 2012-07-10 | 2015-12-24 | Astellas Pharma Inc. | Pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, and method for screening compound comprised in said pharmaceutical composition |
| CN105916840B (zh) * | 2014-01-14 | 2019-01-08 | 安斯泰来制药株式会社 | 吲哚化合物 |
| KR20180120701A (ko) | 2016-02-12 | 2018-11-06 | 아스테라스 세이야쿠 가부시키가이샤 | 테트라히드로이소퀴놀린 유도체 |
| CN116496251A (zh) * | 2023-04-25 | 2023-07-28 | 浙江理工大学 | 一种1h-吲哚-2-酰胺化合物的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2737725B1 (fr) | 1995-08-08 | 1997-10-31 | Valentonine | Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament |
| WO1997032871A1 (en) | 1996-03-08 | 1997-09-12 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| PL190499B1 (pl) | 1996-12-10 | 2005-12-30 | Bristol Myers Squibb Co | Pochodna benzodioksolu, benzofuranu, dihydrobenzofuranu lub benzodioksanu, jej zastosowanie i kompozycja farmaceutyczna |
| FR2907452B1 (fr) | 2006-10-18 | 2008-12-12 | Servier Lab | "nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| CN101605795A (zh) * | 2006-12-08 | 2009-12-16 | 武田药品工业株式会社 | 三环化合物及其药物用途 |
| AU2009275918A1 (en) * | 2008-07-30 | 2010-02-04 | Ferrer Internacional S. A. | 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds |
-
2013
- 2013-07-08 AR ARP130102421 patent/AR091699A1/es unknown
- 2013-07-09 AU AU2013287758A patent/AU2013287758A1/en not_active Abandoned
- 2013-07-09 BR BR112015000709-0A patent/BR112015000709B1/pt not_active IP Right Cessation
- 2013-07-09 CA CA2878663A patent/CA2878663C/en active Active
- 2013-07-09 JP JP2014524827A patent/JP6131951B2/ja not_active Expired - Fee Related
- 2013-07-09 KR KR1020157002758A patent/KR102119372B1/ko active IP Right Grant
- 2013-07-09 US US14/413,746 patent/US9376449B2/en not_active Expired - Fee Related
- 2013-07-09 EP EP13816547.7A patent/EP2873660B1/en active Active
- 2013-07-09 PL PL13816547T patent/PL2873660T3/pl unknown
- 2013-07-09 PT PT138165477T patent/PT2873660T/pt unknown
- 2013-07-09 EA EA201590185A patent/EA026090B1/ru not_active IP Right Cessation
- 2013-07-09 ES ES13816547.7T patent/ES2630653T3/es active Active
- 2013-07-09 TW TW102122700A patent/TW201416351A/zh unknown
- 2013-07-09 MX MX2015000431A patent/MX361463B/es active IP Right Grant
- 2013-07-09 CN CN201380037185.7A patent/CN104428286B/zh not_active Expired - Fee Related
- 2013-07-09 WO PCT/JP2013/068780 patent/WO2014010602A1/ja active Application Filing
-
2014
- 2014-12-23 IL IL236406A patent/IL236406A0/en unknown
-
2015
- 2015-01-05 PH PH12015500003A patent/PH12015500003A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150028340A (ko) | 2015-03-13 |
| MX2015000431A (es) | 2015-03-12 |
| MX361463B (es) | 2018-12-06 |
| EP2873660A1 (en) | 2015-05-20 |
| JP6131951B2 (ja) | 2017-05-24 |
| PT2873660T (pt) | 2016-12-05 |
| BR112015000709A2 (pt) | 2019-11-05 |
| EP2873660A4 (en) | 2015-11-25 |
| WO2014010602A1 (ja) | 2014-01-16 |
| JPWO2014010602A1 (ja) | 2016-06-23 |
| ES2630653T3 (es) | 2017-08-22 |
| TW201416351A (zh) | 2014-05-01 |
| EP2873660B1 (en) | 2016-10-26 |
| CN104428286A (zh) | 2015-03-18 |
| PH12015500003A1 (en) | 2015-03-02 |
| IL236406A0 (en) | 2015-02-26 |
| KR102119372B1 (ko) | 2020-06-05 |
| US9376449B2 (en) | 2016-06-28 |
| CN104428286B (zh) | 2017-03-08 |
| EA026090B1 (ru) | 2017-02-28 |
| AU2013287758A1 (en) | 2015-01-22 |
| CA2878663C (en) | 2020-08-04 |
| EA201590185A1 (ru) | 2015-04-30 |
| BR112015000709B1 (pt) | 2021-10-13 |
| PL2873660T3 (pl) | 2017-02-28 |
| CA2878663A1 (en) | 2014-01-16 |
| US20150203505A1 (en) | 2015-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR090488A1 (es) | Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos | |
| AR093144A2 (es) | Inhibidores de polimerasa viral | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR091208A1 (es) | Derivados de piperidina | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR096613A1 (es) | Moduladores de la acetil-coa carboxilasa | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR095351A1 (es) | Inhibidores de histona desacetilasa (hdac) | |
| AR100940A1 (es) | Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados | |
| AR091699A1 (es) | Derivado de indol carboxamida | |
| AR096614A1 (es) | Moduladores de la acetil-coa carboxilasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |